Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 135062-02-1 | Product Number: R0179
Repaglinide
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic Acid
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 200MG |
NT$3,160
|
15 | 1 | Contact Us | |
| 1G |
NT$10,920
|
5 | 28 | Contact Us |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | R0179 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__3__6N__2O__4 = 452.60 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 135062-02-1 |
| Reaxys Registry Number | 8238956 |
| PubChem Substance ID | 253661221 |
| Merck Index (14) | 8136 |
| MDL Number | MFCD00906179 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 131.0 to 135.0 °C |
| Specific rotation [a]20/D | +7.0 to +10.0 deg(C=1,MeOH) |
Properties (reference)
| Melting Point | 133 °C |
| Specific Rotation | 9° (C=1,MeOH) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dusts or mists. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P405 : Store locked up. |
Related Laws:
| RTECS# | DI0876305 |
Transport Information:
| H.S.code* | 2933.39-000 |
Application
Repaglinide: A Fast-Acting Insulin-Releasing Agent
Repaglinide, a carbamoylmethyl benzoic acid derivative, is a fast-acting insulin-releasing agent. Its mechanism of action is partly similar to that of the sulfonylureas such as glibenclamide [G0382] which binds to the sulfonylurea binding sites on pancreatic β-cells resulting in reducing blood glucose. For details, repaglinide stimulates the release of insulin from pancreatic β-cells by closing ATP-sensitive potassium channels, which results in the opening of calcium channels in the β-cells. Repaglinide is metabolized by CYP2C8 and CYP3A4 enzymes. Repaglinide is used for the treatment of type 2 diabetes. For your reference, [E0928] is a synthetic intermediate of repaglinide. (The product is for research purpose only.)
References
- Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
- Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus (a review)
- Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus
- Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin
- Ionization, lipophilicity and solubility properties of repaglinide
- Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.